Recon: Medtronic wins FDA nod for hypertension device despite expert panel misgivings; FDA lists recall of B. Braun Medical pump system as Class I

• Merck cough drug doesn’t pass panel scrutiny (STAT)
• FDA approves Medtronic high blood pressure device despite a negative advisory panel vote (STAT)
• What Eli Lilly’s Zepbound reveals about the intricate process of naming drugs today (STAT)
• The FDA is at a crossroads on cell and gene therapies (STAT)
• FDA identifies recall of B. Braun Medical pump system as most serious (Reuters)
• Eli Lilly extends tender offer to buy Point Biopharma after low participation (Reuters)
• US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy (Reuters)

• U.K., pharma industry strike deal for how the NHS pays for medicines (STAT) (Reuters)
• Exclusive: Manufacturer Lonza says it will not fill obesity drug syringes (Reuters)
• 'Faster together': AstraZeneca breaks into clinical services business with new company launch, lining up two CRO partners to start (Endpoints)
• Q&A with Judith Ng-Cashin, CRO Novotech's chief medical officer, on 2023 and beyond (Endpoints)
•  

• Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots (STAT)
• CRISPR’s pioneers reflect on the first gene-editing treatment (STAT)
• Bayer recalls one lot of cancer drug Vitrakvi due to contamination (Reuters)
• Bayer woes pile up as blood thinner drug trial fails (Reuters)
• Researchers return to Alzheimer's vaccines, buoyed by recent drug success (Reuters)
• Wegovy craze was all the rage on Q3 earnings calls (Reuters)
• CAR-T cell therapies infused into brain shrink tumors in two glioblastoma studies (Endpoints)
• Obesity and diabetes biotech Carmot Therapeutics files for IPO (Endpoints)
• Q32 Bio to take Homology Medicines’ Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions (Endpoints)

• Hospitals put tech spending on a tight leash, raise the bar for pilots (STAT)
• Amgen lines up new AI biotech partner in PostEra to develop small molecule medicines (Endpoints)
• Q3 recap: Medtech firms grapple with layoffs, GLP-1s and China slowdown (MedTech Dive)
• FDA acts on industry call for clarity about scope of device shortage reporting rules (MedTech Dive)

• How a major hospital shows just how inflated hospital list prices are (STAT)
• Merck loses bid to hold Bayer responsible for talc foot powder claims (Reuters)
• Mother of autistic children lodges complaint over emissions from Sanofi's Depakine drug plant -Le Monde (Reuters)
• Biden taps Vanderbilt’s Kimryn Rathmell to succeed Bertagnolli as the NIH's cancer chief (Endpoints)
• US to offer more free COVID tests nationwide (Reuters)